UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, ~~D.C.~~ DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of ~~report~~ Report (Date of earliest event reported): ~~September~~October 2119, ~~2009~~ 2011

~~Particle Drilling~~Commission ~~Technologies,~~File ~~Inc.~~Number: 000-53750

~~(Exact Name~~PROTEONOMIX, ~~of Registrant as Specified in Its Charter)~~INC.

~~Nevada~~(Name of Registrant in Its Charter)

(State or Other Jurisdiction of Incorporation)

Delaware

(State or Other Jurisdiction of
Incorporation or Organization)

13-3842844

(I.R.S. Employer Identification No.)

187 Mill Lane Mountainside, New Jersey

(Address of Principal Executive Offices)

07052

(Zip Code)

973-544-6116

(Issuer’s Telephone Number, Including Area Code)

000-30819	20-1563395
(Commission File Number)	(I.R.S. Employer Identification No.)
5611 Baird Court
Houston, Texas	77041
(Address of Principal Executive Offices)	(Zip Code)

N/A

~~Registrant’s telephone~~(Former ~~number~~name or former address, ~~including~~if ~~area~~changed ~~code:~~since ~~(713)~~last ~~223-3031~~report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~ -1~~.03 Bankruptcy or Receivership.~~-

~~Particle Drilling~~Section Technologies, Inc (PDTI) today announced that in the near future it will voluntarily file a Form 15 with the United States Securities and Exchange Commission. Upon the filing of the Form 15, PDTI’s obligation to file periodic and current reports with the SEC, including Forms 10-K, 10-Q and 8~~-K, will~~ be suspended. PDTI expects the registration of its class of common stock will be suspended 90 days after it files the Form 15 with the SEC. PDTI’s Board of Directors voted unanimously to file the Form 15 after the order of the Federal Bankruptcy Court for the Southern District of Texas entered on September 1, 2009, confirming PDTI’s Second Amended Joint Disclosure Statement, Confirming PDTI’s Second Amended Chapter 11 Plan of Liquidation and Approving the Sale Thereunder. The Order Granting Final Approval to Debtor’s Second Amended Joint Disclosure Statement, Confirming Debtor’s Second Amended Chapter 11 Plan of Liquidation and Approving Sale Thereunder is filed as an exhibit to this Current Report on Form 8-K ~~and~~Other ~~is incorporated by reference herein.~~Events

Item 98.01 ~~Financial~~- ~~Statements~~Other ~~and Exhibits.~~Events

Proteonomix, Inc. (cthe "Company") issued ~~Exhibits~~a press release, dated October 19, 2011, entitled- Proteonomix, Inc. (PROT) To Move Forward with Offshore Stem Cell Testing The press release is in its entirety below:

~~Exhibit~~Proteonomix, NoInc. ~~Description~~(PROT) ofTo ~~Exhibit~~Move ~~No.~~Forward with Offshore Stem Cell Testing

99MOUNTAINSIDE, NJ--October 19, 2011-- PROTEONOMIX, INC.~~1 Order~~ ~~Granting~~(OTCBB:PROT), ~~Final~~a ~~Approval~~biotechnology tocompany ~~Debtor’s~~focused ~~Second~~on ~~Amended~~developing ~~Joint~~therapeutics ~~Disclosure Statement~~based upon the use of human cells and their derivatives, ~~Confirming~~announced ~~Debtor’s~~today ~~Second~~that ~~Amended~~it ~~Chapter~~intends 11to ~~Plan~~move forward with the testing of ~~Liquidation~~its ~~and Approving~~StromaCel ~~Sale~~technology ~~Thereunder~~through its PRTMI subsidiary or its affiliates. The Company decided to examine the possibility of testing its cardiac stem cell treatment offshore in light of the progress toward its trial of UMK-121, its stem cell treatment for patients awaiting liver transplant to overcome End Stage Liver Disease (“ESLD”), in the United States.

~~THE INFORMATION~~Michael ~~CONTAINED~~Cohen, INPresident ~~THIS~~of ~~CURRENT~~the ~~REPORT~~Company, ~~INCLUDING~~stated: ~~EXHIBITS~~“Since we progress toward the commencement of our trial of UMK-121 in the United States, ~~SHALL~~we ~~NOT~~have ~~BE DEEMED~~decided ~~“FILED”~~to ~~FOR~~explore ~~THE~~the ~~PURPOSES~~possible OFtesting ~~SECTION~~of 18our OFcardiac ~~THE~~treatment ~~SECURITIES~~offshore ~~AND~~in ~~EXCHANGE~~order ~~ACT OF~~to ~~1934,~~reduce ASthe ~~AMENDED,~~cost ~~NOR~~of ~~SHALL~~bringing ITthe BEcardiac ~~DEEMED~~treatment ~~INCORPORATED~~to BYmarket. This ~~REFERENCE~~strategic ~~INTO~~decision ~~ANY REGISTRATION~~is ~~STATEMETN~~being ORmade ~~OTHER~~in ~~FILING~~recognition ~~PURSUANT~~of TOthe ~~THE~~increasing ~~SECURITIES~~costs ~~ACT~~associated OFwith ~~1933, AS~~bringing ~~AMENDED,~~a ~~EXCEPT~~new ASdrug ~~OTHERWISE~~to ~~EXPRESSLY~~market ~~STATED~~in INthe ~~SUCH FILING~~United States through the NDA (New Drug Application) process and the availability of expert medical testing capabilities offshore at a fraction of the cost.”

~~SIGNATURES~~Mr. Cohen continued: “Once we have established the efficacy of our cardiac stem cell treatment offshore and have commenced foreign sales, then we will be in a better financial position to pursue the NDA in the United States.” We have been approached by one group that has expressed interest in exploring such a possibility and we will follow through with this in the coming weeks. Meanwhile we will seek out others interested in a similar transaction keeping mind at all times that any such deal would have to provide immediate benefit to our shareholders,”

~~Pursuant to~~About ~~the requirements of the Securities Exchange Act of 1934~~Proteonomix, ~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized~~Inc.:

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, National Stem Cell, PRTMI and THOR Biopharma. Proteoderm, Inc. is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). National Stem Cell, Inc. is Proteonomix's operating subsidiary. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.

Forward-looking statements:

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

-2-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTEONOMIX, INC.

Dated: October 21, 2011

By: /s/ Michael Cohen

Name: Michael Cohen

Chief Executive Officer

-3-

PARTICLE DRILLING TECHNOLOGIES, INC.

September 21, 2009

/s/ JIM B. TERRY

Name: Jim B. Terry

Title: President and Chief Executive Officer

Filing Compare · PARTICLE DRILLING TECHNOLOGIES INC/NV